Researcher
Bart VAN WIJMEERSCH
- Keywords:Biomedical sciences (incl. biochemistry)
- Disciplines:Autoimmunity, Inflammation, Innate immunity, Transplantation immunology, Medical imaging and therapy not elsewhere classified, Neuroanatomy, Neurophysiology, Rehabilitation
Affiliations
- Rehabilitation Sciences (Faculty)
Member
From1 Sep 2018 → Today - Rehabilitation Research Center (Research group)
Member
From1 Sep 2018 → Today - Rehabilitation Sciences & Physiotherapy (Department)
Member
From1 Sep 2018 → Today - Biomedical Research Institute (Research institute)
Member
From1 Sep 2008 → Today - Immunology - Biochemistry (Research group)
Member
From1 Sep 2008 → 31 Aug 2018 - Physiology - Biochemistry - Immunology (Department)
Member
From1 Sep 2008 → 31 Aug 2018 - Faculty of Medicine and Life Sciences (Faculty)
Member
From1 Sep 2008 → 31 Aug 2018 - Medical Basic Sciences (Division)
Member
From1 Sep 2008 → 30 Sep 2009
Projects
1 - 9 of 9
- Empirical development of a multimodal prognostication tool to guide treatment-strategy for Multiple SclerosisFrom1 Nov 2022 → TodayFunding: BOF - doctoral mandates
- Identification of multiple sclerosis-specific cytotoxic CD4 T cellsFrom1 Mar 2022 → 1 Mar 2023Funding: Industrial enterprises
- MACSiMiSE-BRAIN: Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And NeurodegenerationFrom1 Oct 2021 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Short term changes in "Radiomic" features predict long-term treatment effectivenessFrom1 Sep 2019 → 31 Aug 2020Funding: Foreign foundations, funds with scientific view
- COGNITIVE-MOTOR INTERFERENCES DURING WALKING IN PERSONS WITH MULTIPLE SCLEROSIS: ASSESSMENT, REHABILITATION STRATEGIES AND NEURAL CORRELATESFrom1 Sep 2017 → 31 Aug 2021Funding: BOF - Doctoral projects
- Multiple sclerosis, a multidisciplinary approachFrom1 Jan 2015 → 31 Dec 2019Funding: FWO scientific research network
- T lymphocytes: from basic biology to immunotherapyFrom1 Oct 2012 → 31 Dec 2017Funding: IUAP-VII
- BOF NI project: A role for expanded CD4+CD28null T cells in patients with multiple sclerosis?From1 Jan 2012 → 31 Dec 2015Funding: BOF - Doctoral projects
- Multiple Sclerosis, a multidisciplinary appraochFrom1 Jan 2010 → 31 Dec 2014Funding: FWO scientific research network
Publications
31 - 40 of 160
- Cognitive improvements accompanied with WPAI improvements in OCR-treated patients with RRMS: 96-week CASTING data(2022)
Authors: P. Vermersch, G. Comi, C. Oreja-Guevara, A. Siva, Bart VAN WIJMEERSCH, H. Wiendl, R. Buffels, T. Kuenzel, R. Benedict
Pages: 788 - 789 - A real-world single-centre analysis of the safety and efficacy of cladribine tablets for relapsing multiple sclerosis(2022)
Authors: Sofie AERTS, Hamza KHAN, Deborah SEVERIJNS, Veronica POPESCU, Liesbet PEETERS, Bart VAN WIJMEERSCH
Pages: 892 - Determinants of therapeutic lag in multiple sclerosis(2021)
Authors: I Roos, E Leray, F Frascoli, R Casey, JWL Brown, D Horakova, EK Havrdova, M Debouverie, M Trojano, F Patti, et al.
Pages: 1838 - 1851 - Characterisation of the innate and adaptive immune system after ocrelizumab treatment in multiple sclerosis(2021)
Authors: Lien BECKERS, Paulien BAETEN, Dries SWINNEN, Ibrahim HAMAD, S. Tavernier, Bart VAN WIJMEERSCH, Veronica POPESCU, Markus KLEINEWIETFELD, Bieke BROUX, Judith FRAUSSEN, et al.
Pages: 777 - 778 - Outcomes in Alemtuzumab-Treated Patients With Thyroid Adverse Events: 6-Year Pooled CARE-MS Data(2021)
Authors: Colin Dayan, Beatriz Lecumberri, Ilaria Muller, Sashiananthan Ganesananthan, Samuel F. Hunter, Krzysztof W. Selmaj, Hans-Peter Hartung, Eva K. Havrdova, Christopher C. LaGanke, Tjalf Ziemssen, et al.
- Efficacy and safety of ocrelizumab in patients with RRMS with suboptimal response to prior disease-modifying therapies: 3-year data from CASTING and LIBERTO 1-year interim results(2021)
Authors: Bart VAN WIJMEERSCH, G. Comi, C. Oreja-Guevara, H. Wiendl, J. Wuerfel, R. Buffels, P. Dirks, T. Kuenzel, K. Kadner, P. Vermersch
Pages: 543 - 544 - Differential effects and discriminative validity of motor and cognitive tasks varying in difficulty on cognitive–motor interference in persons with multiple sclerosis(2021)
Authors: Renee VELDKAMP, Alon Kalron, Ilse BAERT, Paivi Hamalainen, Andrea Tacchino, Mieke D'HOOGE, Xavier GIFFROY, Fanny VAN GEEL, Joke RAATS, Karin CONINX, et al.
Pages: 1924 - 1938 - Application of step and beat alignment approaches and its effect on gait in progressive multiple sclerosis with severe cerebellar ataxia: A proof of concept case study(2021)
Authors: Lousin MOUMDJIAN, Bart Moens, Bart VAN WIJMEERSCH, Marc Leman, Peter FEYS
Pages: 492 - 495 - Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score(2021)
Authors: Amy Kunchok, Jeannette Lechner-Scott, Franco Granella, Maria Trojano, Raed Alroughani, Patrizia Sola, Diana Ferraro, Alessandra Lugaresi, Marco Onofrj, Serkan Ozakbas, et al.
Pages: 695 - 705 - IgD-CD27-double negative (DN) B cells of multiple sclerosis patients are mature memory cells that can migrate towards pro-inflammatory chemokines(2021)
Authors: Lien BECKERS, Gwendoline MONTES DIAZ, Luisa Maria Villar, Bart VAN WIJMEERSCH, Veronica POPESCU, Veerle SOMERS, Judith FRAUSSEN
Pages: 187